A 13-week, randomized, double-blind, multicenter, placebo-controlled study to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia.
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Pregabalin (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Nov 2016 Results of a retrospective analysis from NCT00394901, NCT00553475, NCT00407745, NCT00424372, NCT00553280, NCT01202227 studies, published in the Clinical Drug Investigation
- 26 Jan 2009 Trial phase changed from III to II/III as reported by ClinicalTrials.gov.
- 24 Sep 2008 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.